Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05310110
Other study ID # 202200004A3
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date April 12, 2022
Est. completion date August 24, 2023

Study information

Verified date February 2024
Source Chang Gung Memorial Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Laryngeal mask airway (LMA) is currently the most widely used supraglottic airway device with advantages of simple and fast placement, reduced anesthesia drug use, more stable hemodynamics, and less throat discomfort after anesthesia compared to endotracheal intubation. Some studies claimed the use of muscle relaxants or local anesthetics (sprays or lubricants containing local anesthetics) for the throat before LMA placement can reduce the dosage of induction agents and postoperative throat complications. In modern society, more and more elderly people undergo elective surgery with the need of general anesthesia. However, they are the more vulnerable population with tendency of greater hemodynamic changes with more induction agent usage. Propofol is one of the most used induction agents which may lead to a drop in blood pressure. The objective of this study is to observe whether the dose of propofol and the changes in hemodynamics can be reduced by using muscle relaxants or laryngeal local anesthetics in elderly who receiving general anesthesia with LMA insertion.


Recruitment information / eligibility

Status Completed
Enrollment 96
Est. completion date August 24, 2023
Est. primary completion date August 24, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 65 Years and older
Eligibility Inclusion Criteria: - American Society of Anesthesiologists (ASA) physical status I-III - Age: over 65 years - Elective orthopedic surgery undergo general anesthesia in supine position Exclusion Criteria: - Anticipated difficult airway (Mallampati score 3-4), limited mouth opening, intra-oral and pharyngeal pathology - Risk of pulmonary aspiration of gastric contents (full stomach) - Obesity (Body mass index > 35) - Significant lung abnormalities (low lung compliance, high airway resistance, impaired oxygenation) - Loosening teeth - Allergic to Cisatracurium or Lidocaine - Failure in successful LMA insertion after second attempts

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
10% lidocaine spray
10% lidocaine spray 3 puff for the throat before induction
Placebo of lidocaine spray
Normal saline spray 3 puff for the throat before induction
Cisatracurium
Intravenous cisatracurium 0.12 mg/kg during induction
Placebo of cisatracurium
Intravenous normal saline during induction
Propofol
The dosage of intravenous propofol for the first subjects was predetermined for each arm, and the dosage for the subsequent subjects would be determined according to the response of the previous subjects using the Dixon's up-and-down method with a step size of 0.25 mg/kg. If the subjects had no movement and stable hemodynamic status during and after the laryngeal mask airway (LMA) placement, the predetermined dosage of propofol for the subsequent subject would be decreased by 0.25 mg/kg. On the other hand, if the subjects had obvious movement, failure to LMA placement, and significant hemodynamic changes, the predetermined dosage of propofol for the subsequent subject would be increased by 0.25 mg/kg.

Locations

Country Name City State
Taiwan Linkup Chang Gung Memorial Hospital Taoyuan City

Sponsors (1)

Lead Sponsor Collaborator
Chang Gung Memorial Hospital

Country where clinical trial is conducted

Taiwan, 

Outcome

Type Measure Description Time frame Safety issue
Primary Propofol requirement The minimal propofol requirement dose was defined as the median effective dose (ED50) of movement or increased mean arterial pressure (MAP) to no movement or stable MAP. The ED50 is the average of the crossover midpoints found during conducting the Dixon's up-and-down method. one minute after propofol infusion
Secondary Non-invasive blood pressure (NIBP) Using the non-invasive blood pressure machine to collect the systolic blood pressure, diastolic blood pressure, and mean arterial pressure 0 minute, 1 minute, 2 minute, 3 minute, 4 minute, 5 minute, 10 minute after LMA placement
Secondary Heart rate (HR) Using the electrocardiogram monitor to collect the real-time heart rate 0 minute, 1 minute, 2 minute, 3 minute, 4 minute, 5 minute, 10 minute after LMA placement
Secondary Oxygen saturation (SpO2) Using the pulse oximeter to collect the real-time oxygen saturation 0 minute, 1 minute, 2 minute, 3 minute, 4 minute, 5 minute, 10 minute after LMA placement
Secondary Peak pressure (P peak) of the airway One of the monitoring parameter demonstrated on the mechanical ventilator 0 minute after LMA placement
Secondary Mean pressure (P mean) of the airway One of the monitoring parameter demonstrated on the mechanical ventilator 0 minute after LMA placement
Secondary Ease of jaw opening A factor for evaluating the condition of LMA insertion Procedure (At the same time of LMA placement)
Secondary Ease of LMA insertion A factor for evaluating the condition of LMA insertion Procedure (At the same time of LMA placement)
Secondary Coughing or gagging Symptoms which suggest non-optimal condition of LMA insertion Within 1 minute after LMA placement
Secondary Hiccups Symptoms which suggest non-optimal condition of LMA insertion Within 1 minute after LMA placement
Secondary Head or body movement Symptoms which suggest non-optimal condition of LMA insertion Within 1 minute after LMA placement
Secondary Laryngospasm Laryngospasm is defined as airway obstruction with assumption that LMA is correctly placed, which is also a factor for evaluating the condition of LMA insertion Within 1 minute after LMA placement
Secondary Attempts for LMA insertion The number of attempts for LMA insertion Procedure (At the same time of LMA placement)
Secondary Complications Including sore throat, dysphagia, dysphonia One hour after LMA removal
See also
  Status Clinical Trial Phase
Recruiting NCT06063798 - Respiratory Effects of Flow-Controlled Ventilation and Jet Ventilation in Patients Undergoing Laryngotracheal Surgery N/A
Not yet recruiting NCT05035069 - Efficacy and Safety of Ciprofol Compared to Propofol for Nonintubated General Anesthesia in Patients Undergoing TAVR Phase 4
Completed NCT03861364 - Hemodynamics During Induction of General Anesthesia With High and Low Propofol Dose. Phase 4
Completed NCT02711280 - The Effect of Anesthetics on Oxidative Stress and Apoptosis Status in Children N/A
Completed NCT01199471 - Estimate the Behavior of Chinese Anesthesiologists Practicing General Anesthesia With Sevoflurane N/A
Completed NCT00917033 - Tracheal Intubation of Morbidly Obese Patients. GlideScope Versus Direct Laryngoscopy Phase 4
Completed NCT00391885 - Target-controlled Infusion of Propofol and Remifentanil During General Anaesthesia Guided by Entropy Phase 4
Completed NCT00552617 - A Bridging Trial Comparing Sugammadex (Org 25969) at Reappearance of T2 in Japanese and Caucasian Participants. Part B: Caucasian Participants (P05971) Phase 2
Completed NCT03705026 - Relationship Between Genetic Polymorphism and Postoperative Nausea and Vomiting in Chinese Han Population
Completed NCT00552929 - A Bridging Trial Comparing Sugammadex (Org 25969) at 1-2 Post-Tetanic Count (PTC) in Caucasian Participants. Part B (P05974) Phase 2
Completed NCT00475215 - Safety and Efficacy of Sugammadex (Org 25969, MK-8616) in Participants With or Having a Past History of Pulmonary Disease (19.4.308) (P05932) (MK-8616-017) Phase 3
Completed NCT00298831 - Use of Sugammadex at the End of Case in Routine Anesthesia (MK-8616-023) Phase 3
Recruiting NCT03943745 - EEG Changes During Induction of Propofol Anesthesia
Completed NCT03697642 - Nasopharyngeal Airway Guide Nasogastric Tube Placement N/A
Completed NCT04595591 - Observation of Propofol Titration at Different Speeds N/A
Not yet recruiting NCT05841316 - The ED95 Dose of Sugammadex to Reverse Rocuronium-Induced Deep Neuromuscular Block Back to Shallow Neuromuscular Block
Completed NCT04532502 - Impact of Anesthetic Environment the Sex Ratio of the Children of Female Assistants
Completed NCT03330236 - EEG - Guided Anesthetic Care and Postoperative Delirium N/A
Recruiting NCT06205212 - High-flow Nasal Oxygenation During Preoxygenation and Atelectasis N/A
Completed NCT00379613 - Use of Sugammadex Administered at 5 Minutes After Administration of 1.2 mg/kg Esmeron® (19.4.205)(P05942) Phase 2